Tags

Type your tag names separated by a space and hit enter

Supplementation of n-3 Polyunsaturated Fatty Acids for Major Depressive Disorder: A Randomized, Double-Blind, 12-Week, Placebo-Controlled Trial in Korea.
Ann Nutr Metab 2015; 66(2-3):141-8AN

Abstract

BACKGROUND

Controversy over the efficacy of n-3 polyunsaturated fatty acids (PUFAs) in depression continues to this day. The present study investigated the hypothesis that n-3 PUFA supplementation reduces depressive symptoms in Korean patients with major depressive disorder.

METHODS

In a randomized, double-blind, placebo-controlled, 12-week, parallel-group trial, 35 patients with Center for Epidemiological Studies Depression Scale Korean version (CES-D-K) scores ≥25 and depression confirmed by a psychiatrist were assigned to take either 3 capsules of n-3 PUFAs (1,140 mg of EPA + 600 mg of DHA; n = 18) or placebo (olive oil + safflower oil; n = 17).

RESULTS

Supplementation with n-3 PUFAs significantly reduced Clinical Global Impression Improvement (CGI-I) scores as compared with intake of placebo using intention-to-treat analysis with last-observation-carried-forward after adjusting for energy, fat, and fish intake. However, the CES-D-K, Hamilton Depression Rating Scale-17, and Clinical Global Impression Scale scores did not significantly differ between the n-3 PUFA and placebo groups. After supplementation with n-3 PUFAs, the erythrocyte levels of n-3 PUFAs were significantly increased, but n-6 PUFA levels were decreased.

CONCLUSIONS

n-3 PUFAs demonstrated an advantage over placebo that did not reach clinical significance, although CGI-I score was significantly decreased in the n-3 PUFA group as compared with the placebo group.

Authors+Show Affiliations

Department of Food and Nutrition, College of Human Ecology, Hanyang University, Seongdong-gu, Seoul, Republic of Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25824637

Citation

Park, Yongsoon, et al. "Supplementation of N-3 Polyunsaturated Fatty Acids for Major Depressive Disorder: a Randomized, Double-Blind, 12-Week, Placebo-Controlled Trial in Korea." Annals of Nutrition & Metabolism, vol. 66, no. 2-3, 2015, pp. 141-8.
Park Y, Park YS, Kim SH, et al. Supplementation of n-3 Polyunsaturated Fatty Acids for Major Depressive Disorder: A Randomized, Double-Blind, 12-Week, Placebo-Controlled Trial in Korea. Ann Nutr Metab. 2015;66(2-3):141-8.
Park, Y., Park, Y. S., Kim, S. H., Oh, D. H., & Park, Y. C. (2015). Supplementation of n-3 Polyunsaturated Fatty Acids for Major Depressive Disorder: A Randomized, Double-Blind, 12-Week, Placebo-Controlled Trial in Korea. Annals of Nutrition & Metabolism, 66(2-3), pp. 141-8. doi:10.1159/000377640.
Park Y, et al. Supplementation of N-3 Polyunsaturated Fatty Acids for Major Depressive Disorder: a Randomized, Double-Blind, 12-Week, Placebo-Controlled Trial in Korea. Ann Nutr Metab. 2015;66(2-3):141-8. PubMed PMID: 25824637.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Supplementation of n-3 Polyunsaturated Fatty Acids for Major Depressive Disorder: A Randomized, Double-Blind, 12-Week, Placebo-Controlled Trial in Korea. AU - Park,Yongsoon, AU - Park,Yoo-Sin, AU - Kim,Seok Hyeon, AU - Oh,Dong Hoon, AU - Park,Yong-Chon, Y1 - 2015/03/24/ PY - 2014/11/12/received PY - 2015/01/30/accepted PY - 2015/4/1/entrez PY - 2015/4/1/pubmed PY - 2016/1/21/medline SP - 141 EP - 8 JF - Annals of nutrition & metabolism JO - Ann. Nutr. Metab. VL - 66 IS - 2-3 N2 - BACKGROUND: Controversy over the efficacy of n-3 polyunsaturated fatty acids (PUFAs) in depression continues to this day. The present study investigated the hypothesis that n-3 PUFA supplementation reduces depressive symptoms in Korean patients with major depressive disorder. METHODS: In a randomized, double-blind, placebo-controlled, 12-week, parallel-group trial, 35 patients with Center for Epidemiological Studies Depression Scale Korean version (CES-D-K) scores ≥25 and depression confirmed by a psychiatrist were assigned to take either 3 capsules of n-3 PUFAs (1,140 mg of EPA + 600 mg of DHA; n = 18) or placebo (olive oil + safflower oil; n = 17). RESULTS: Supplementation with n-3 PUFAs significantly reduced Clinical Global Impression Improvement (CGI-I) scores as compared with intake of placebo using intention-to-treat analysis with last-observation-carried-forward after adjusting for energy, fat, and fish intake. However, the CES-D-K, Hamilton Depression Rating Scale-17, and Clinical Global Impression Scale scores did not significantly differ between the n-3 PUFA and placebo groups. After supplementation with n-3 PUFAs, the erythrocyte levels of n-3 PUFAs were significantly increased, but n-6 PUFA levels were decreased. CONCLUSIONS: n-3 PUFAs demonstrated an advantage over placebo that did not reach clinical significance, although CGI-I score was significantly decreased in the n-3 PUFA group as compared with the placebo group. SN - 1421-9697 UR - https://www.unboundmedicine.com/medline/citation/25824637/Supplementation_of_n_3_Polyunsaturated_Fatty_Acids_for_Major_Depressive_Disorder:_A_Randomized_Double_Blind_12_Week_Placebo_Controlled_Trial_in_Korea_ L2 - https://www.karger.com?DOI=10.1159/000377640 DB - PRIME DP - Unbound Medicine ER -